Cost-effectiveness of the implementation of [⁶⁸Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging.

ABSTRACT:

Background

Despite its high specificity, PSMA PET/CT has a moderate to low sensitivity of 40-50% for pelvic lymph node detection, implicating that a negative PSMA PET/CT cannot rule out lymph node metastases. This study investigates a strategy of implementing PSMA PET/CT for initial prostate cancer staging and treatment planning compared to conventional diagnostics. In this PSMA PET/CT strategy, a bilateral extended pelvic lymph node dissection (ePLND) is only performed in case of a negative PSMA PET/CT; in case of a positive scan treatment planning is solely based on PSMA PET/CT results.

Method

A decision table and lifetime state transition model were created. Quality-adjusted life years and health care costs were modelled over lifetime.

Results

The PSMA PET/CT strat

SUBMITTER: van der Sar ECA 

PROVIDER: S-EPMC9375809 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature